Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||KLH conjugated synthetic peptide between 274-303 amino acids from the C-terminal region of human ALS2CR2|
|Purification||Size-exclusion - Dialysis, Ammonium sulfate precipitation|
|Contains||0.09% sodium azide|
|Storage Conditions||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
ALS2CR2 potentiates the antiapoptotic activity of XIAP by enhancing XIAP-mediated activation of JNK1 (MAPK8) and other JNK family members, but not by modulating XIAP-mediated caspase inhibition. Expression of a catalytically inactive TAK1 (MAP3K7) mutant blocks the XIAP/ALS2CR2 activation of JNK1. In vivo coprecipitation experiments show that both ALS2CR2 and XIAP interact with TAK1 and TRAF6. It has been proposed that XIAP-mediated protection from apoptosis utilizes both a JNK1 activation pathway that involves ALS2CR2 and a caspase inhibition pathway that is independent of ALS2CR2.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
ALS2CR2; amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2; amyotrophic lateral sclerosis 2 chromosomal region candidate gene 2 protein; ILP-interacting protein ILPIPA; ILPIP; pseudokinase ALS2CR2; Serine/threonine-protein kinase ALS2CR2; STRAD beta
ALS2CR2; CALS-21; ILPIP; ILPIPA; PAPK; PRO1038; STRADB